New Aspects in the Diagnosis and Treatment of Hodgkin's Disease

In the field of Hodgkin's lymphoma, many new data have been collected during the last decade both on the cell of origin of this disease and on more effective therapies to cure the majority of pa­ tients even in the advanced stages. Therefore, it seems to be justi­ fied to compile these new data in a special volume of Recent Re­ sults in Cancer Research. This volume summarizes the contribu­ tions presented at the First International Symposium on Hodgkin's Disease that took place in Cologne (FRG) on October 2-3, 1988. There is little doubt that the Hodgkin and Reed-Sternberg (H and RS) cells and their variants represent the malignant population in Hodgkin's lymphoma; however, there is still a fierce debate as to the possible cell of origin of Hand RS cells. Many of the problems confounding earlier research into this question were related to the difficulty or virtual impossibility, of obtaining purified populations of Hand RS cells. Most of the recent progress stems from the establishment of permanent cell lines of Hand RS cells in culture.

Inhalt

Pathology and Cell Biology of Hodgkin's Disease.- Pathology of Hodgkin's Disease: Anything New?.- Immunology of Hodgkin and Reed-Sternberg Cells.- DNA Gene Rearrangement Studies in Hodgkin's Disease and Related Lymphomas: A Contribution to Their Cellular Origin..- Genetics of Hodgkin's Lymphoma.- Hodgkin's Disease Derived Cell Lines.- Biology of Hodgkin Cell Lines.- Phenotypic and Genotypic Analysis of Two Cell Lines Derived from Hodgkin's Disease Tissue Biopsies.- The Typical Reed-Sternberg Phenotype and I g Gene Rearrangements of Hodgkin's Disease Derived Cell Line ZO Indicating a B-Cell Origin.- Characterization of Hodgkin's Disease Derived Cell Line HDLM-2.- A New Hypothesis on the Cellular Origin of Reed-Sternberg and Hodgkin Cells Based on the Immunological and Molecular Genetic Analysis of the KM-H2 Line.- A Marker and Putative Pathoantigen of Hodgkin's Cells.- Development in Diagnostic Procedures.- Radiolabeled Monoclonal Antibodies Against Reed-Sternberg Cells for in Vivo Imaging of Hodgkin's Disease by Immunoscintigraphy.- Diagnostic Strategies and Staging Procedures for Hodgkin's Lymphoma: Bone Marrow Scintigraphy and Magnetic Resonance Imaging.- Therapeutic Strategies.- Overviews.- Radiotherapy Trials in Hodgkin's Disease.- Current Status of Chemotherapy for Hodgkin's Disease.- Report on Recent and Current Clinical Trials.- Risk Factor Adapted Treatment of Hodgkin's Lymphoma: Strategies and Perspectives.- Reduced Combined Radiotherapy and Chemotherapy for Hodgkin's Disease - Risk-Adapted Treatment Approach.- Hodgkin's Disease: The Milan Cancer Institute Experience with MOPP and ABVD.- EORTC Lymphoma Cooperative Group Studies in Clinical Stage I-II Hodgkin's Disease - 1963 1987.- Current Stanford Clinical Trials for Hodgkin's Disease.- Results and Prognostic Factors Following Optimal Treatment in Advanced Hodgkin's Disease.- Two Cycles of MOPP and Definitive Radiotherapy for Stage IIIA and III B Hodgkin's Disease.- Risk Factor Adapted Treatment of Hodgkin's Lymphoma in Childhood: Strategies and Results of Three Consecutive Multicenter Studies in the Federal Republic of Germany.- Hodgkin's Disease in Children: Adaptation of Treatment to Risk Factors.- Role of Bone Marrow Transplantation in the Treatment of Hodgkin's Lymphoma.- Conventional Salvage Therapy for Hodgkin's Lymphoma.- High-Dose Combination Chemotherapy with Cyclophosphamide, Carmustine, Etoposide, and Autologous Bone Marrow Transplantation in 60 Patients with Relapsed Hodgkin's Disease: The M. D. Anderson Experience.- Treatment of Resistant Hodgkin's Lymphoma with Bone Marrow Transplantation in Italy.- Preliminary Results of Autologous Bone Marrow Transplantation in the Management of Resistant Hodgkin's Disease: Experience of the Bloomsbury Transplant Group at University College, London.- Bone Marrow Transplantation in the Treatment of Hodgkin's Lymphoma: Problems, Remaining Challenges, and Future Prospects.- Acute and Late Side Effects of Treatment.- Quality of Life During and After Treatment of Hodgkin's Disease.- Risk of Secondary Acute Leukemia and Preleukemia After Hodgkin's Disease: The Institut Gustave-Roussy Experience.